Roth Capital Upgrades Salix Pharmaceuticals (SLXP) to Buy
More News related to SLXP
- Salix Pharmaceuticals to Present at Piper Jaffray Conference
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Salix Pharmaceuticals, Ltd. Completes Sale of 6.325 Million Shares of Common Stock
- Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
- Salix Pharma (SLXP) Prices 5.5M Share Offering
More News related to Upgrades
- Shares of Brocade (BRCD) Outperforming as Oscar Gruss Upgrades to Buy
- Kinross (KGC) Jumps Higher as Gold Breaks $1,200, JPMorgan Upgrades to Overweight
- Raymond James Upgrades PSS World Medical (PSSI) to Outperform
- Capital One Southcoast Upgrades Penn Virginia (PVA) to Add; Turning Bullish After Data Release
- Raymond James Upgrades CPFL Energia S.A. (CPL) to Outperform
Roth Capital upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Hold to Buy. Price target $12.50.
To see more analyst ratings on SLXP Click Here.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract.
Related Categories
UpgradesStocks Mentioned
+0.62Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
